S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
66,000% upside on tiny biotech? (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
66,000% upside on tiny biotech? (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
BREAKING: Tiny biotech successfully treats blindness (Ad)
The Retail Sector is on the cusp of a major breakout
Bloomin’ Brands could blossom in 2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
66,000% upside on tiny biotech? (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
66,000% upside on tiny biotech? (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
BREAKING: Tiny biotech successfully treats blindness (Ad)
The Retail Sector is on the cusp of a major breakout
Bloomin’ Brands could blossom in 2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
66,000% upside on tiny biotech? (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
66,000% upside on tiny biotech? (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
BREAKING: Tiny biotech successfully treats blindness (Ad)
The Retail Sector is on the cusp of a major breakout
Bloomin’ Brands could blossom in 2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dropbox’s stock is a falling knife worth catching
66,000% upside on tiny biotech? (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
66,000% upside on tiny biotech? (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
BREAKING: Tiny biotech successfully treats blindness (Ad)
The Retail Sector is on the cusp of a major breakout
Bloomin’ Brands could blossom in 2024

Alzamend Neuro (ALZN) Competitors

$0.90
+0.01 (+1.13%)
(As of 02/23/2024 ET)

ALZN vs. GNPX, APM, UPC, PULM, KZIA, SHPH, GTBP, LIPO, HILS, and GRAY

Should you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Genprex (GNPX), Aptorum Group (APM), Universe Pharmaceuticals (UPC), Pulmatrix (PULM), Kazia Therapeutics (KZIA), Shuttle Pharmaceuticals (SHPH), GT Biopharma (GTBP), Lipella Pharmaceuticals (LIPO), Hillstream BioPharma (HILS), and Graybug Vision (GRAY). These companies are all part of the "pharmaceutical preparations" industry.

Alzamend Neuro vs.

Genprex (NASDAQ:GNPX) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends.

In the previous week, Alzamend Neuro's average media sentiment score of 0.00 equaled Genprex'saverage media sentiment score.

Company Overall Sentiment
Genprex Neutral
Alzamend Neuro Neutral

Genprex received 192 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 64.90% of users gave Genprex an outperform vote.

CompanyUnderperformOutperform
GenprexOutperform Votes
196
64.90%
Underperform Votes
106
35.10%
Alzamend NeuroOutperform Votes
4
100.00%
Underperform Votes
No Votes

14.1% of Genprex shares are owned by institutional investors. Comparatively, 6.4% of Alzamend Neuro shares are owned by institutional investors. 11.5% of Genprex shares are owned by company insiders. Comparatively, 10.9% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genprex has a beta of -0.47, suggesting that its share price is 147% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500.

Alzamend Neuro has a consensus target price of $22.50, indicating a potential upside of 2,411.44%. Given Genprex's higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Genprex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genprex
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Alzamend Neuro
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Alzamend Neuro is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenprexN/AN/A-$23.74M-$24.80-0.18
Alzamend NeuroN/AN/A-$14.88M-$1.51-0.59

Alzamend Neuro's return on equity of -194.71% beat Genprex's return on equity.

Company Net Margins Return on Equity Return on Assets
GenprexN/A -194.71% -156.61%
Alzamend Neuro N/A -612.26%-207.52%

Summary

Genprex and Alzamend Neuro tied by winning 6 of the 12 factors compared between the two stocks.


Get Alzamend Neuro News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALZN vs. The Competition

MetricAlzamend NeuroPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.27M$6.74B$5.11B$7.57B
Dividend YieldN/A2.74%2.86%3.87%
P/E Ratio-0.597.41157.0613.99
Price / SalesN/A194.363,052.2766.14
Price / CashN/A18.6198.6255.40
Price / Book1.914.604.394.60
Net Income-$14.88M$156.18M$113.02M$207.29M
7 Day Performance5.40%0.99%0.93%-1.13%
1 Month Performance-2.58%10.73%7.30%3.57%
1 Year Performance-88.09%3.87%10.68%5.54%

Alzamend Neuro Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNPX
Genprex
1.1732 of 5 stars
$4.29
-2.5%
N/A-92.2%$6.39MN/A-0.1731
APM
Aptorum Group
0 of 5 stars
$1.80
-3.7%
N/A-54.0%$6.43M$1.30M0.0018News Coverage
UPC
Universe Pharmaceuticals
0 of 5 stars
$1.76
-28.5%
N/A-57.4%$6.37M$32.31M0.00225Gap Down
PULM
Pulmatrix
1.3747 of 5 stars
$1.78
-3.3%
$10.00
+463.4%
-44.1%$6.48M$6.07M-0.4028Analyst Report
KZIA
Kazia Therapeutics
2.2215 of 5 stars
$0.40
+11.2%
$2.00
+403.9%
-63.8%$6.49M$20,000.000.002,021Upcoming Earnings
Gap Up
SHPH
Shuttle Pharmaceuticals
0 of 5 stars
$0.38
flat
N/A-79.9%$6.12MN/A-0.987News Coverage
GTBP
GT Biopharma
1.6207 of 5 stars
$4.43
+3.7%
$105.00
+2,270.2%
-79.2%$6.11MN/A-0.492Gap Up
LIPO
Lipella Pharmaceuticals
0 of 5 stars
$1.00
flat
N/A-53.9%$6.05M$184,156.000.005
HILS
Hillstream BioPharma
0 of 5 stars
$0.39
flat
N/A-71.7%$6.85MN/A-0.541Gap Up
High Trading Volume
GRAY
Graybug Vision
0 of 5 stars
$4.36
-2.9%
N/A-48.8%$6.85MN/A-2.5227Gap Up
High Trading Volume

Related Companies and Tools

This page (NASDAQ:ALZN) was last updated on 2/24/2024 by MarketBeat.com Staff